目的 探究平消片联合甲苯磺酸索拉非尼片治疗中晚期原发性肝癌的临床疗效。方法 选取2016年1月—2017年8月在南阳市中心医院接受规范治疗的中晚期原发性肝癌患者116例为研究对象，将入选患者按抗肿瘤方案分为对照组和治疗组，每组各58例。对照组口服甲苯磺酸索拉非尼片，400 mg/次，2次/d。治疗组在对照组治疗的基础上口服平消片，0.92 g/次，3次/d。两组患者均连续治疗12周。观察两组的临床疗效，比较两组的生活质量、癌痛程度、肿瘤标志物和生存情况。结果 治疗后，对照组和治疗组的临床获益率分别为70.69%、84.48%，客观缓解率分别为25.86%、51.72%，两组比较差异有统计学意义（P<0.05）。治疗后，两组KPS评分、SF-36评分均高于治疗前，VAS评分均低于治疗前，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组KPS评分、SF-36评分高于对照组，VAS评分低于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组血清AFP水平均明显低于治疗前，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组血清AFP水平明显低于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，治疗组中位生存期明显长于对照组，1年存活率显著高于对照组，两组比较差异有统计学意义（P<0.05）。结论 平消片联合甲苯磺酸索拉非尼片治疗中晚期原发性肝癌具有较好的临床疗效，能改善患者生活质量、生存情况，具有一定临床推广应用价值。

Objective To observe the effect of Pingxiao Tablets combined with Sorafenib Tosylate Tablets in treatment of middle- advanced primary liver cancer. Methods Patients (116 cases) with middle-advanced primary liver cancer in Nanyang Central Hospital from January 2016 to August 2017 were randomly divided into control and treatment groups, and each group had 58 cases. Patients in the control group were po administered with Sitagliptin Phosphate Tablets, 100 mg/time, once daily. Patients in the treatment group were po administered with Pingxiao Tablets on the basis of the control group, 0.3 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and quality of life, cancer pain degree, tumor markers, and survival situations in two groups were compared. Results After treatment, the clinical benefit rates in the control and treatment groups were 70.69% and 84.48%, respectively, and the objective response rates in the control and treatment groups were 25.86% and 51.72%, respectively, and there was difference between two groups (P<0.05). After treatment, KPS scores and SF-36 scores in two groups were significantly increased, but VAS scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of AFP in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the levels of AFP in the treatment group was significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the median survival time in the treatment group was significantly longer than that in the control group, and the 1-year survival rate in the treatment group was significantly higher than that in the control group, and there was difference between two groups (P<0.05). Conclusion Pingxiao Tablets combined with Sorafenib Tosylate Tablets has clinical curative effect in treatment of middle-advanced primary liver cancer, can improve quality of life and survival situation, which has a certain clinical application value.

国家自然科学基金青年科学基金资助项目（81702757）